Acceder

Participaciones del usuario mugiwara

mugiwara 11/10/19 20:32
Ha respondido al tema Farmas USA
Dopping del bueno:Federal Reserve to buy $60bn of Treasury bills per monthSize of operation shocks Wall Street analysts who expected more conservative approachThe Federal Reserve is poised to begin at least a six-month operation to buy about $60bn of Treasury bills per month, as the US central bank seeks to ease cash shortages that caused a recent spike in the overnight cost of borrowing.https://www.ft.com/content/baa7e796-ec38-11e9-85f4-d00e5018f061
Ir a respuesta
mugiwara 04/10/19 14:41
Ha respondido al tema Farmas USA
hostia sí! Que leñazo no? De 6 a 3 en unos pocos días. Mis disculpas...entre que no estoy para nada por labores bolsísticas estos días y no la sigo... Pues igual lo de exel ya ha pasado también XDDDPIRS
Ir a respuesta
mugiwara 04/10/19 11:44
Ha respondido al tema Farmas USA
EXELSegún Cowen soltarán datos fase 3 en octubre, aunque según ellos debería ser prácticamente un win-win, porque si sale mal bajará un 0%... También dicen que habrá datos de las PIRS de Investing, ahí habría mucho más meneo arriba o abajo.Key events october 2019
Ir a respuesta
mugiwara 25/09/19 15:07
Ha respondido al tema Farmas USA
A un año de les elecciones (noviembre 2020) con todo lo que supone eso solo de tiempo para su posible aprobación en las 2 cámaras etc, para mi suena a inicio de la campaña electoral, no más. Llevan un par de años con el impeachment en la boca y no han hecho nada hasta ahora.Por otro lado si el mercado se lo tomara en serio me imagino unos futuros en -3/-5% y no planos como están ahora.Respondiendo a tu pregunta: los traders siempre estarán contentos con jaleo y buenos meneos de árbol ;-)
Ir a respuesta
mugiwara 20/09/19 13:19
Ha respondido al tema Farmas USA
REGNHay más sobre Dupixent: THE LANCET PUBLISHES RESULTS FROM TWO POSITIVE PHASE 3 TRIALS OF DUPIXENT® (DUPILUMAB) IN SEVERE CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP)  https://newsroom.regeneron.com/news-releases/news-release-details/lancet-publishes-results-two-positive-phase-3-trials-dupixentr 
Ir a respuesta
mugiwara 20/09/19 13:02
Ha respondido al tema Farmas USA
CBIOAyer me salí a 6,05 con ligeras pérdidas, nulo interés ahora mismo, goteo a la baja, ya volveremosREGNCHMP RECOMMENDS APPROVAL OF DUPIXENT® (DUPILUMAB) FOR SEVERE CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS  https://newsroom.regeneron.com/news-releases/news-release-details/chmp-recommends-approval-dupixentr-dupilumab-severe-chronic  A final decision on the Dupixent application by the European Commission (EC) is expected in the coming months. (Normalmente son unos 3 meses)No espero que esto la vaya a mover, pero bueno, mejor una recomendación de aprobación en Europa que nada...
Ir a respuesta
mugiwara 19/09/19 13:27
Ha respondido al tema Farmas USA
Chicharraco ADXSAyer movió un volumen muy destacable, prácticamente desde mínimos, buena vela. Ahí lo dejo, para quién guste de esos indicadores para meterle a un chicharro (8 mill de MC). Yo desde luego no la voy a tocar ni con un palo.De momento sin news (que yo haya visto).Notificación de delisting la semana pasada, pero hasta marzo de 2020 no sería efectivo: Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.On September 11, 2019, Advaxis, Inc. (“Advaxis”) received written notice from the staff (the “Staff”) of the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that Advaxis was not in compliance with Nasdaq Listing Rule 5450(b)(1)(C) because Advaxis’ Market Value of Publicly Held Shares (“MVPHS”) has been below $5,000,000 for the last 30 consecutive business days. Nasdaq calculates MVPHS based on the last reported principal stockholders table (which Advaxis filed on July 24, 2019) by subtracting from the total shares of common stock outstanding any shares held by officers, directors or any person who beneficially owns more than 10% of the total shares outstanding. The notification of noncompliance has no immediate effect on the listing or trading of Advaxis common stock on the Nasdaq Global Select Market under the symbol “ADXS,” and Advaxis is currently monitoring the MVPHS and evaluating its alternatives, if appropriate, to regain compliance with this rule. In accordance with Nasdaq Listing Rule 5810(c)(3)(D), Advaxis has 180 calendar days from the date of such notice, or until March 9, 2020, to regain compliance with the minimum MVPHS. To regain compliance, Advaxis’ MVPHS must be at least $5,000,000 for a minimum of 10 consecutive business days during the 180 calendar day compliance period. If Advaxis regains compliance, Nasdaq will provide Advaxis with written confirmation and will close the matter. 
Ir a respuesta
mugiwara 16/09/19 09:55
Ha respondido al tema Farmas USA
jaja Perdón, me daba pereza escribir explicaciones y lo he resulto entrecomillando Teva...
Ir a respuesta
mugiwara 16/09/19 09:25
Ha respondido al tema Farmas USA
"TEVA"  Purdue Pharma files for bankruptcy protection  Purdue’s board on Sunday approved the much-anticipated bankruptcy filing, days after reaching a tentative deal to settle some 2,000 opioid lawsuits filed by local governments, Native American tribes and states.Purdue and a group of state attorneys general had been negotiating for months to settle the lawsuits over the opioid crisis to avoid a trial, expected to begin in October.  https://www.cnbc.com/2019/09/16/oxycontin-maker-purdue-pharma-files-for-bankruptcy-protection.html 
Ir a respuesta
mugiwara 13/09/19 14:25
Ha respondido al tema Farmas USA
TEVA Entra en el mundillo de la distribución de productos terapéuticos derivados del cannabis...de momento en Israel y luego ya se verá según normativas propias de cada país. InterCure: Canndoc signs strategic distribution agreement with Teva's S.L.E. InterCure announced that subsidiary Canndoc has entered into a strategic distribution agreement with Salomon, Levin, Elstein, which is owned by Teva Pharmaceuticals. Under terms of the agreement, S.L.E. will distribute Canndoc's GMP products to pharma clients, including hospitals, health maintenance organizations and all pharmacies in Israel, including pharmacy chains. In the future, as regulatory approvals allow, S.L.E. will provide logistics capability for exporting Canndoc's products to countries that support regulations for the sale and distribution of cannabis products for medical use.
Ir a respuesta